Drugs /

octreotide

Back to Drugs List

Overview

Generic Name(s):
octreotide
Trade Name(s):
Sandostatin Lar, Sandostatin, Longastatina, Samilstin, Sandostatina, and Sandostatine
NCI Definition [1]:
A synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.

Clinical Trials

View Clinical Trials for octreotide

Octreotide has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating octreotide, 1 is phase 1 (1 open), 1 is phase 2 (0 open), and 1 is phase 3 (1 open).

BIRC5 Expression, ERBB2 Amplification, and HER2 Overexpression are the most frequent biomarker inclusion criteria for octreotide clinical trials.

Breast carcinoma, digestive system neuroendocrine neoplasm, and gastrointestinal neuroendocrine tumors are the most common diseases being investigated in octreotide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Octreotide
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Octreotide
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating octreotide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Sandostatin, Sandostatin LAR, Longastatina, Samilstin, Sandostatina, Sandostatine, l-cysteinamide, d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-n-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2-7)-disulfide, (r-(r*,r*))-, d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-n-[(1r,2r)-2-hydroxy-1-(hyroxymethyl)propyl]-l-cysteinamide, cyclic (2->7)-disulfide, octreotide, octreotide preparation, sms-201-995, octreotidum, octrotide, d-phenylalanyl-l-cysteinyl-l-phenyl-alanyl-d-tryptophyl-l-lysyl-l-threonyl-n-[2-hydroxy-1-(hydroxymethyl)propyl]-l-cysteinamide cyclic (2->7)-disulfide, octreotida, d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-l-cysteinyl-l-threoninol cyclic (2->7)-disulfide, octreotide preparation (product), octreotide, octreotide [chemical/ingredient], octreotide (substance)
Drug Categories [2]:
Somatostatin receptor agonists
NCIT ID [1]:
C711
SNOMED ID [1]:
C-A0010

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.